GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
Gilead doubles down on Arcus
Will a TIGIT refocus see the stars finally align for the partners?
A changing of the guard in stomach cancer?
Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.
ASCO Plenary – Gilead and Arcus pedal hard with TIGIT
A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.
Bristol seeks novelty in TIGIT
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
